$SLDB

Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.

Solid Biosciences Inc. (SLDB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001707502 false 0001707502 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

Solid Biosciences Inc. (SLDB) has received orphan drug designation from the European Commission for SGT-003, its investigational treatment for Duchenne muscular dystrophy. This designation provides significant benefits like market exclusivity in the EU and regulatory assistance, highlighting the company's commitment to rare disease therapies. Despite this positive development, the company holds a low GF Score™ of 39 and has experienced significant insider selling, which investors should consider.

Solid Biosciences Inc. sponsored the SADS Foundation's Challenging Cases in Inherited Arrhythmias Symposium, demonstrating its commitment to genetic heart rhythm research. This participation aligns with the company's broader focus on advancing precision gene therapy and initiating human trials for conditions like Friedreich ataxia. Solid Biosciences continues to emphasize genetic approaches for treating inherited disorders.

Guggenheim has initiated coverage on Solid Biosciences (SLDB) with a Buy rating, projecting a potential FDA approval for its lead therapy, SGT-003, for Duchenne muscular dystrophy. Analyst Debjit Chattopadhyay set a price target of $26 per share, noting that while the company faces financial challenges and insider selling, its strong liquidity and high institutional ownership are positives. The biotechnology firm's valuation shows a high P/B ratio, and it carries inherent risks associated with regulatory challenges and high drug development costs.

Solid Biosciences (SLDB) announced positive interim data from its Phase 1/2 INSPIRE DUCHENNE trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. The data showed robust microdystrophin expression, improved muscle integrity biomarkers, and stabilization/improvement in cardiac function. The company has also reached an agreement with the FDA for its Phase 3 IMPACT DUCHENNE trial, with screening ongoing and first dosing expected in Q1 2026.

CHARLESTOWN, Mass., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Solid Biosciences Inc. ( Nasdaq: SLDB ) ( the "Company" or "Solid" ) , a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor ...

CHARLESTOWN, Mass., Sept. 25, 2025 ( GLOBE NEWSWIRE ) -- Solid Biosciences Inc. ( NASDAQ: SLDB ) , a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003, a ...

- Non-exclusive license for Solid's proprietary, next generation capsid, AAV-SLB101, to accelerate development of Kinea Bio's gene therapy for dysferlin-related limb-girdle muscular dystrophy ...

CHARLESTOWN, Mass., Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Solid Biosciences Inc. SLDB ( the "Company" or "Solid" ) , a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences: